STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News:
Karo Bio (STO:KARO)
* A 12 week phase II study with KB2115 in patients with primary hypercholesterolemia has been successfully completed. KB2115 was efficacious in LDL lowering and safe with respect to a broad range of parameters reflecting effects on heart, bone, muscle and thyroid function
* The clinical candidate in the Merck collaboration has been discontinued. A backup compound has been selected for preclinical development
